Cytokine Release Syndrome (CRS) Grading

ورودی‌های بالینی بیمار

حداقل ۰ — حداکثر ۱۲۰ • واحد: years

پنل نتیجه و تصمیم بالینی
در انتظار ورودی‌ها
crs assessment
—grade
آماده برای ارزیابی

پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.

طبقات خطر و بازه‌های امتیاز:
  • Grade 1 - Mild1–1
  • Grade 2 - Moderate2–2
  • Grade 3 - Severe3–3
  • Grade 4 - Life-threatening4–4
Direct Clinical Answer

The Cytokine Release Syndrome (CRS) Grading calculator is designed for bedside assessing severity of cytokine release syndrome in immunotherapy patients, particularly those receiving CAR-T cell therapy and other immune effector cell therapies in clinical practice. The resulting score directly guides clinician decision-making regarding adjusting systemic.

Clinical Guidelines & Evidence

Assesses severity of cytokine release syndrome in immunotherapy patients, particularly those receiving CAR-T cell therapy and other immune effector cell therapies. CRS is an acute inflammatory process marked by a spectrum of clinical symptoms and substantial elevations of serum cytokines.

Clinical Indication

The Cytokine Release Syndrome (CRS) Grading is indicated for bedside clinical practice to support Assesses severity of cytokine release syndrome in immunotherapy patients, particularly those receiving CAR-T cell therapy and other immune effector cell therapies. CRS is an acute inflammatory process marked by a spectrum of clinical symptoms and substantial elevations of serum cytokines.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

Target Population

Target population comprises Patients with solid tumors or hematologic malignancies undergoing staging, systemic therapy tolerability assessment, or prognostic stratification. Clinical application is indicated across Medical oncology clinics, chemotherapy infusion suites, inpatient oncology services, and palliative care.

Limitations & Contraindications

Prognostic indices provide statistical cohort survival estimates and must not replace individualized patient goals of care.

Clinical Pearls & Action Plan

Standardized functional performance status (ECOG or Karnofsky) is an independent determinant of chemotherapy tolerance and survival. Guideline pearl: Treatment should be individualized based on patient comorbidities and clinical status.

Formula & Variables:

CRS Grade determined by highest severity parameter: fever requirement + maximum of (hypotension grade, oxygen requirement grade, organ toxicity grade)

Input Parameters

NameTypeRequiredDescription
fever_presentstringYesPresence of fever (≥38°C) or fever suppressed by anti-pyretic/anti-cytokine therapy
hypotension_statusstringYesHypotension status and intervention requirements
oxygen_requirementstringYesOxygen support requirements
organ_toxicity_gradeintegerYesHighest grade of organ toxicity (using CTCAE criteria, excluding fever and hypotension)
patient_ageintegerNoPatient age in years (for risk stratification)(years)
comorbidities_presentstringNoPresence of significant comorbidities that may affect CRS management

Score Interpretation & Guidance

RangeStageDescription
1–1Grade 1 - MildMild symptoms
2–2Grade 2 - ModerateModerate intervention required
3–3Grade 3 - SevereAggressive intervention required
4–4Grade 4 - Life-threateningLife-threatening symptoms
5–5Grade 5 - DeathDeath related to CRS

Evidence-Based References (EBM)

  • Lee DW, Santomasso BD, Locke FL, et al. ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. Biol Blood Marrow Transplant. 2019;25(4):625-638. doi: 10.1016/j.bbmt.2018.12.758.DOI: 10.1016/j.bbmt.2018.12.758
  • Porter D, Frey N, Wood PA, Weng Y, Grupp SA. Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel. J Hematol Oncol. 2018;11(1):35. doi: 10.1186/s13045-018-0571-y.DOI: 10.1186/s13045-018-0571-y
  • Neelapu SS, Tummala S, Kebriaei P, et al. Chimeric antigen receptor T-cell therapy - assessment and management of toxicities. Nat Rev Clin Oncol. 2018;15(1):47-62. doi: 10.1038/nrclinonc.2017.148.DOI: 10.1038/nrclinonc.2017.148
  • Maude SL, Barrett D, Teachey DT, Grupp SA. Managing cytokine release syndrome associated with novel T cell-engaging therapies. Cancer J. 2014;20(2):119-122. doi: 10.1097/PPO.0000000000000035.DOI: 10.1097/PPO.0000000000000035

Related calculators